+Compare
RGEN
Stock ticker:
NASDAQ
AS OF
Jun 24 closing price
Price
$165.88
Change
+$5.55 (+3.46%)
Capitalization
9.2B

RGEN Repligen Corp Forecast, Technical & Fundamental Analysis

a developer of biologic drugs
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Jun 24, 2022

RGEN in upward trend: price rose above 50-day moving average on June 23, 2022

RGEN moved above its 50-day moving average on June 23, 2022 date and that indicates a change from a downward trend to an upward trend. In 30 of 33 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 24, 2022. You may want to consider a long position or call options on RGEN as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RGEN just turned positive on June 24, 2022. Looking at past instances where RGEN's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in of 361 cases, the price rose further within the following month. The odds of a continued upward trend are .

RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 352 cases where RGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for RGEN crossed bearishly below the 50-day moving average on June 16, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.206) is normal, around the industry mean (7.126). P/E Ratio (65.359) is within average values for comparable stocks, (91.157). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.021) among similar stocks. P/S Ratio (13.055) is also within normal values, averaging (90.334).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

AI

View a ticker or compare two or three

AI
A.I. Advisor
published Earnings

RGEN is expected to report earnings to fall 21.74% to 72 cents per share on July 26

Repligen Corp RGEN Stock Earnings Reports
Q2'22
Est.
$0.72
Q1'22
Beat
by $0.20
Q4'21
Beat
by $0.16
Q3'21
Beat
by $0.14
Q2'21
Beat
by $0.27
The last earnings report on April 27 showed earnings per share of 92 cents, beating the estimate of 72 cents. With 695.85K shares outstanding, the current market capitalization sits at 9.20B.
AI
A.I. Advisor
published General Information

General Information

a developer of biologic drugs

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
41 Seyon Street, Building 1
Phone
+1 781 250-0111
Employees
1852
Web
https://www.repligen.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FLXS21.330.76
+3.69%
Flexsteel Industries
PNR47.031.50
+3.29%
Pentair plc
AEHL1.060.02
+1.92%
Antelope Enterprise Holdings Limited
IVT26.29-0.37
-1.39%
InvenTrust Properties Corp
EVGO7.68-0.45
-5.54%
EVgo

RGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGEN has been closely correlated with BIO. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then BIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGEN
1D Price
Change %
RGEN100%
+3.46%
BIO - RGEN
68%
Closely correlated
+0.45%
WST - RGEN
68%
Closely correlated
+0.76%
DHR - RGEN
66%
Closely correlated
+0.65%
BRKR - RGEN
66%
Loosely correlated
-1.05%
QGEN - RGEN
63%
Loosely correlated
+4.02%
More